von Willebrand factor A domain containing 5B1Genealiases: []
Q-omics provides the consensus-scored VWA5B1 profile across patient tissues and cancer cell-line models. VWA5B1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, VWA5B1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, VWA5B1 RNA expression shows 14,096 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, KIRC, and TGCT as cancer lineages where VWA5B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VWA5B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VWA5B1 survival associations across molecular data types. VWA5B1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VWA5B1 RNA expression–survival associations across cancer types. High VWA5B1 expression shows unfavorable associations in LGG, STAD and MESO, but favorable associations in SCLC, BRCA and ACC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for VWA5B1 RNA expression.
This table summarizes VWA5B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VWA5B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VWA5B1 shows lower tumor expression in KIRC, KIRP, LUSC and LUAD and higher tumor expression in STAD and KICH. The KIRC box plot shows higher VWA5B1 RNA expression in normal versus tumor tissue (log2 FC = −1.450, t-test p < 0.001).
This table shows molecular features associated with VWA5B1 in patient tissues and cancer cell lines. In patient samples, VWA5B1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VWA5B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and STOMACH.
